Print Page    E-mail Page    RSS    E-mail Alerts 

Press Releases

<< Back
Printer Friendly Version View printer-friendly version
Bellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences

WARREN, N.J., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, and the Ladenburg Thalmann 3rd Annual Healthcare Conference.

Rodman & Renshaw 19th Annual Global Investment Conference
Date: Tuesday, September 12
Time: 9:35 am Eastern Time
Location: The Lotte New York Palace Hotel, Kennedy I Ballroom
Webcast:  http://wsw.com/webcast/rrshq27/blph
   
Ladenburg Thalmann 3rd Annual Healthcare Conference
Date: Tuesday, September 26
Time: 1:30 pm Eastern Time
Location:  Sofitel Hotel, New York City, Orleans Ballroom
Webcast: http://wsw.com/webcast/ladenburg3/blph  

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development.  For more information, please visit www.bellerophon.com.

Contact
Bellerophon Therapeutics:
Fabian Tenenbaum, Chief Executive Officer
(908) 574-4819

LifeSci Advisors
Bob Yedid, Managing Director
(646) 597-6989
bob@lifesciadvisors.com

Primary Logo

Bellerophon Therapeutics Inc.